COLL Collegium Pharmaceutical Inc.

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025.

Details of the event are as follows:

Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM®, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Cheryl Wheeler

Head of Corporate Communications



EN
01/04/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces $25 Million Accelerated Share Repurchase Program

Collegium Announces $25 Million Accelerated Share Repurchase Program STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of th...

May 12, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports First Quarter 2025 Financial Results and Highlights ...

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1’25 with Cash, Cash Equivale...

May 8, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report First Quarter 2025 Financial Results on May 8, 202...

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will...

April 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Con...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Real-World Data at PainConnect 2025, the American...

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch